ALNY Q3 2018 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-87.9% YoY

Gross Profit

$2M93.4% margin

Operating Income

-$255M-12303.4% margin

Net Income

-$245M-11855.1% margin

EPS (Diluted)

$-2.43

QoQ Revenue Growth

-93.1%

Cash Flow

Operating Cash Flow

-$154M

Free Cash Flow

-$199M

Stock-Based Comp.

$88M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$198M

Stockholders' Equity

$1.5B

Cash & Equivalents

$317M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$17M	-87.9%
Gross Profit	$2M	$17M	-88.7%
Operating Income	-$255M	-$126M	-102.4%
Net Income	-$245M	-$123M	-99.5%

Revenue Segments

Product

$460,000100%